Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia

• Status: Completed
• Trial end date: 0000-00-00
• Target enrollment: 108
• Participant gender: Both

Summary

The aim of this study is to assess longer term safety and effectiveness of Dysport®.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: abobotulinumtoxinA; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA
• Last Updated: 2010-06-17

Criteria

Inclusion Criteria:

• Subjects enrolled in the Y-47-52120-051 study, who have completed all study visits up to Week 12, or up to Week 4 in the event of an early withdrawal

• Returned to pre-treatment status as judged by the Investigator

Exclusion Criteria:

• Pure anterocollis or pure retrocollis

• Known antibodies to botulinum toxin type A

• Requirement for botulinum toxin injections to site(s) other than the neck and unable to avoid such treatment for the duration of the study

• Known significant underlying swallowing or respiratory abnormality which might be exacerbated by botulinum toxin treatment